Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
about
New Antiretroviral Treatment for HIVAbacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective StudyKidney Disease and HIV Infection.HIV infection and bone disease.What's new for antiretroviral treatment in women with HIVViability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations.Hepatitis C co-infection is associated with an increased risk of incident chronic kidney disease in HIV-infected patients initiating combination antiretroviral therapy.Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with PreserveTenofovir alafenamide as part of a salvage regimen in a patient with multi-drug resistant HIV and tenofovir-DF-associated renal tubulopathy.Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected AdultsBrief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study.Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide.Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.A Review of the Efficacy and Safety of Genvoya(®) (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection.Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.Tenofovir Alafenamide.Acute Care Management of the HIV-Infected Patient: A Report from the HIV Practice and Research Network of the American College of Clinical Pharmacy.HIV and Bone Complications: Understudied Populations and New Management Strategies.Emtricitabine + tenofovir alafenamide for the treatment of HIV.Elvitegravir for the treatment of HIV.Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.Single-Tablet Regimens for the Treatment of HIV-1 Infection.Association of Increased Urinary Albumin With Risk of Incident Clinical Fracture and Rate of Hip Bone Loss: the Osteoporotic Fractures in Men Study.Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study.Incidence of renal Fanconi syndrome in patients taking antiretroviral therapy including tenofovir disoproxil fumarate.Kidney Disease in HIV: Moving beyond HIV-Associated Nephropathy.Effects of a Nutritional Protein-Rich Drink on the Pharmacokinetics of Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide, and Tenofovir Compared With a Standard Meal in Healthy Japanese Male Subjects.Risk of End-Stage Renal Disease in HIV-Positive Potential Live Kidney Donors.Bone mineral density reductions after tenofovir disoproxil fumarate initiation and changes in phosphaturia: a secondary analysis of ACTG A5224s.Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a rHigher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.Patterns of vitamin D, parathyroid hormone and c-terminal telopeptide of collagen type 1 in Caucasian and African descent HIV-infected populations in Central EuropeShort Communication: Resolution of Tenofovir Disoproxil Fumarate Induced Fanconi Syndrome with Switch to Tenofovir Alafenamide Fumarate in a HIV-1 and Hepatitis B Coinfected Patient.Ledipasvir and tenofovir drug interaction in human immunodeficiency virus-hepatitis C virus coinfected patients: Impact on tenofovir trough concentrations and renal safety.Strength in Amalgamation: Newer Combination Agents for HIV and Implications for Practice.Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug.Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens.
P2860
Q28069829-1DD326E7-A7FC-4614-96FD-3E33A094CA4AQ28554630-F02EA548-E163-419B-A831-DF262129DF49Q30234837-4CC0FD4C-B64E-4611-B57B-9F6D69BDD071Q30249771-079FD6E6-9CED-4D31-A3B3-76A513B4B4BDQ30391322-BDC65807-B33E-4FE5-BF0F-97FF31B22635Q36275141-C4EA2815-21BB-4F50-A79A-993551809AE3Q36334834-87C86992-5527-41B3-A6BF-583B952E3C24Q37141511-52201403-88D5-422A-BFF1-AA43E5F951DCQ37242504-C571AEC9-4BF0-4ED8-A326-00A83F2BAC2BQ37519831-8BDCABB0-1325-49FB-9689-AE1DBBF04948Q37582471-3894C7BD-609A-4DB8-989D-5F551E55C405Q37604553-3B94BCF0-E8C3-40E4-8285-33A716C67C0EQ37613237-E65F60E4-BFC4-4CD5-8631-33529E08D042Q38756133-79804C9A-2BB9-4257-9A05-5ACD6F385914Q38802093-75FFB17D-DB11-4AE7-85BA-7F2D49DB039EQ38813848-E5D78D24-0EC6-4714-A720-2870AF991E7DQ38836878-17AE4EFA-6449-4DAD-AB6F-A27842EFFCF8Q38868949-7990FD87-BB05-4995-A462-A5203CE8417AQ38910661-0598858C-5FBB-4F9F-9FC3-2B6AB9003DE8Q38920747-6E27CE4A-85F9-40F1-A2EE-962185801B8AQ38978479-428D9BF9-A4A7-485F-BF24-601A2A84AEB0Q38984695-65CD5E9E-4039-47BC-A44A-BDDD138F7D6BQ38987327-4054751A-ADDD-4BCE-B756-A7824BCB82F1Q39002230-E0E89DEC-C804-458E-A833-1A3D34041C59Q39022885-1DF7BADD-93B5-4B6D-A85C-55B59F8CF04AQ39052391-F669363A-6A30-4F16-AEB5-C72A8E719931Q39311308-E98EE58B-14C5-4480-98DC-E9122E44A487Q40099241-8E8E0347-49B6-4D2A-9145-232A5CBFEBEDQ40103229-DFB189B1-C831-4312-B282-A8D8B6D023EDQ40185119-AB9AB281-5B63-41FF-ABC7-A2B5ECD8F81DQ40204367-D3C0E12C-F052-4A8F-BF27-EBAFAD9DF0B3Q40267569-DAD69467-B22F-409F-9A1B-12F52C6791A3Q40288176-41FA49DC-01E5-409B-ACD5-307BDB5CCD33Q41932859-7E2337CF-5961-400D-90EE-A384357ADC9FQ42700121-9054FBAC-259C-4E1A-BF49-B6A9A7C83E92Q43882622-4EC10A9D-F4F7-42CE-BACE-ECFBAD7DA62AQ45326406-A9FCFBE7-CF75-4DC6-8FE4-D9060A025DC8Q45961010-ACC7769A-7EDB-4A31-B366-1D434A7E2271Q47560453-B9EEDF2F-F4C7-4D76-BDDF-ED1BCCA2E485Q47562735-A335CCB3-C517-4928-8777-28B569FF6D3C
P2860
Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Switching to Tenofovir Alafena ...... nter, Open-Label Phase 3 Study
@ast
Switching to Tenofovir Alafena ...... nter, Open-Label Phase 3 Study
@en
type
label
Switching to Tenofovir Alafena ...... nter, Open-Label Phase 3 Study
@ast
Switching to Tenofovir Alafena ...... nter, Open-Label Phase 3 Study
@en
prefLabel
Switching to Tenofovir Alafena ...... nter, Open-Label Phase 3 Study
@ast
Switching to Tenofovir Alafena ...... nter, Open-Label Phase 3 Study
@en
P2093
P2860
P1476
Switching to Tenofovir Alafena ...... nter, Open-Label Phase 3 Study
@en
P2093
Anchalee Avihingsanon
Andrew Cheng
Anton Pozniak
Devi SenGupta
Frank A Post
GS-US-292-0112 Study Team
Gordon Crofoot
Jose R Arribas
Joseph Gathe
Joseph M Custodio
P2860
P304
P356
10.1097/QAI.0000000000000908
P407
P577
2015-11-30T00:00:00Z